Authors
Steve Pedrini, Edith Cowan UniversityFollow
Eugene Hone, Edith Cowan UniversityFollow
Veer B. Gupta, Edith Cowan UniversityFollow
Ian James
Elham Teimouri, Edith Cowan University
Ashley I. Bush
Christopher C. Rowe
Victor L. Villemagne
David Ames
Colin L. Masters
Stephanie Rainey-Smith, Edith Cowan UniversityFollow
Guiseppe Verdile
Hamid R. Sohrabi
Manfred R. Raida
Markus Wenk
Kevin Taddei, Edith Cowan UniversityFollow
Pratishtha Chatterjee
Ian Martins, Edith Cowan UniversityFollow
Simon Laws, Edith Cowan UniversityFollow
Ralph Martins, Edith Cowan UniversityFollow
Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group
Author Identifier
Steve Pedrini
https://orcid.org/0000-0002-6409-8022
Eugene Hone
https://orcid.org/0000-0001-6708-3718
Stephanie Rainey-Smith
https://orcid.org/0000-0001-7328-9624
Kevin Taddei
https://orcid.org/0000-0002-8106-7957
Ian James Martins
https://orcid.org/0000-0002-2390-1501
Simon Laws
https://orcid.org/0000-0002-4355-7082
Ralph Martins
Document Type
Journal Article
Publication Title
Journal of Alzheimer's Disease
Publisher
IOS Press
School
School of Medical and Health Sciences
RAS ID
32180
Funders
Edith Cowan University - Open Access Support Scheme 2020
Abstract
Background:
The link between cholesterol and Alzheimer’s disease (AD) has received much attention, as evidence suggests high levels of cholesterol might be an AD risk factor. The carriage of cholesterol and lipids through the body is mediated via lipoproteins, some of which, particularly apolipoprotein E (ApoE), are intimately linked with AD. In humans, high density lipoprotein (HDL) is regarded as a “good” lipid complex due to its ability to enable clearance of excess cholesterol via ‘cholesterol reverse transport’, although its activities in the pathogenesis of AD are poorly understood. There are several subclasses of HDL; these range from the newly formed small HDL, to much larger HDL.
Objective:
We examined the major subclasses of HDL in healthy controls, mild cognitively impaired, and AD patients who were not taking statins to determine whether there were HDL profile differences between the groups, and whether HDL subclass levels correlated with plasma amyloid-β (Aβ) levels or brain Aβ deposition.
Methods:
Samples from AIBL cohort were used in this study. HDL subclass levels were assessed by Lipoprint while Aβ1–42 levels were assessed by ELISA. Brain Aβ deposition was assessed by PET scan. Statistical analysis was performed using parametric and non-parametric tests.
Results:
We found that small HDL subclass is reduced in AD patients and it correlates with cognitive performance while plasma Aβ concentrations do not correlate with lipid profile or HDL subfraction levels.
Conclusion:
Our data indicate that AD patients exhibit altered plasma HDL profile and that HDL subclasses correlate with cognitive performances.
DOI
10.3233/JAD-200291
Related Publications
Pedrini, S. (2023). An overview of blood-based biomarkers in AD. https://ro.ecu.edu.au/theses/2623
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
Comments
Pedrini, S., Hone, E., Gupta, V. B., James, I., Teimouri, E., Bush, A. I., ... & Martins, R. (2020). Plasma High Density Lipoprotein Small Subclass is Reduced in Alzheimer’s Disease Patients and Correlates with Cognitive Performance. Journal of Alzheimer's Disease, 77(2), 733-744. https://doi.org/10.3233/JAD-200291